Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2024 Earnings Conference Call April 23, 2024 8:30 AM ET Company Participants Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Shawn Bevec - Vice President of Investor Relations Conference Call Participants Patrick Donnelly - Citi Ann Hynes - Mizuho Securities Kevin Caliendo - UBS Taji Phillips - Jefferies ...
Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.
First quarter revenues of $2.37 billion, up 1.5% from 2023 First quarter reported diluted earnings per share ("EPS") of $1.72, down 3.4% from 2023; and adjusted diluted EPS of $2.04, flat with 2023 Full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion; reported diluted EPS now expected to be between $7.57 and $7.82; and adjusted diluted EPS expected to be between $8...
Company's AD-Detect™ Portfolio Offers AB 42/40 and Other Plasma Biomarker Testing, Alongside Traditional Cerebrospinal Fluid and Genetic Tests, to Provide Robust Offering in Brain Health SECAUCUS, N.J. , April 22, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, o...
Aim to demonstrate whole genome sequencing can replace the standard diagnostic cascade, for potentially faster diagnosis and lower costs SECAUCUS, N.J. , April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstr...
A list of top stocks expected to raise dividends in the upcoming week, with increases averaging 8.4% and median 6.8%. Companies included in the list have consistently grown their dividends for at least five years. Comparison of historical returns of stocks to benchmark SCHD, with JPM being the top performer.
Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality evaluation and lowering healthcare costs SECAUCUS, N.J. , March 26, 2024 /PRNewswire/ -- A blood test that analyzes levels of amyloid proteins by highly sensitive mass spectrometry could help physic...
SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial results on Tuesday, April 23, 2024, before the market opens.
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.